As an anticytokine therapy, tocilizumab has been recommended for the management
therapy in patients with severe and serious COVID-19 cases. The association between the …

Severe status of coronavirus disease 2019 (COVID-19) is extremely associated to cytokine
release. Moreover, it has been suggested that blood group is also associated with the …

The new coronavirus disease-2019 (COVID-19) is rapidly spreading around the world and
has been declared an outbreak by WHO. However, the effect of blood groups on COVID-19 …

Objective Predictive parameters that can affect the course of this infection have been the
main topic of research since the beginning of the COVID-19 (Coronavirus disease 2019) …

ABSTRACT Background/Aims: There is a significant increase in proinflammatory cytokine
levels in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients entering …

Introduction Coronavirus disease 2019 (COVID-19) is the ongoing pandemic with multitude
of manifestations and association of ABO blood group in South-East Asian population needs …

Background The COVID-19 pandemic is attributed to SARS-COV-2 virus rapidly spreading
around the world as a global health emergency. The difference in the rate of infection and …

Post-treatment neutrophil to lymphocyte ratio as a prognostic tool in patients treated with
tocilizumab for severe COVID-19 pneumonia - a single center experience Skoči na glavni …

Aim: Many factors have been speculated to explain the COVID-19 complex clinical
phenotype. Due to the inconsistent data published on blood groups and COVID-19, we …

Objectives: This study aimed to investigate the relationship between ABO blood groups and
the mortality rate, disease severity, and length of hospitalization (LOH) in patients with …